Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Ørsted

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Nature Reviews. Urology|November 21, 2012
The link between benign prostatic hyperplasia and prostate cancerDavid D Ørsted, Stig E Bojesen
European Urology|February 13, 2013
Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortalityDavid D Ørsted, Stig E Bojesen, Pia R Kamstrup, et al.
European Urology|June 28, 2011
Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 menDavid D Ørsted, Stig E Bojesen, Sune F Nielsen, et al.
Diabetes Care|May 7, 2017
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized TrialWilliam M Steinberg, John B Buse, Marie Louise Muus Ghorbani, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 5, 2018
Liraglutide and Glycaemic Outcomes in the LEADER TrialBernard Zinman, Michael A Nauck, Heidrun Bosch-Traberg, et al.
JAMA Cardiology|November 14, 2019
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical TrialSubodh Verma, Stephen C Bain, John B Buse, et al.
Journal of Diabetes and Its Complications|June 21, 2016
LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes populationIlhan Satman, Rosangela R Rea, Mats Eriksson, et al.
The New England Journal of Medicine|August 31, 2017
Liraglutide and Renal Outcomes in Type 2 DiabetesJohannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, et al.
Diabetes Care|May 6, 2020
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER TrialJohn B Buse, Stephen C Bain, Johannes F E Mann, et al.
Circulation|December 20, 2018
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or StrokeSubodh Verma, Neil R Poulter, Deepak L Bhatt, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nature Reviews. Urology|November 21, 2012
The link between benign prostatic hyperplasia and prostate cancerDavid D Ørsted, Stig E Bojesen
European Urology|February 13, 2013
Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortalityDavid D Ørsted, Stig E Bojesen, Pia R Kamstrup, et al.
European Urology|June 28, 2011
Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 menDavid D Ørsted, Stig E Bojesen, Sune F Nielsen, et al.
Diabetes Care|May 7, 2017
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized TrialWilliam M Steinberg, John B Buse, Marie Louise Muus Ghorbani, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 5, 2018
Liraglutide and Glycaemic Outcomes in the LEADER TrialBernard Zinman, Michael A Nauck, Heidrun Bosch-Traberg, et al.
JAMA Cardiology|November 14, 2019
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical TrialSubodh Verma, Stephen C Bain, John B Buse, et al.
Journal of Diabetes and Its Complications|June 21, 2016
LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes populationIlhan Satman, Rosangela R Rea, Mats Eriksson, et al.
The New England Journal of Medicine|August 31, 2017
Liraglutide and Renal Outcomes in Type 2 DiabetesJohannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, et al.
Diabetes Care|May 6, 2020
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER TrialJohn B Buse, Stephen C Bain, Johannes F E Mann, et al.
Circulation|December 20, 2018
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or StrokeSubodh Verma, Neil R Poulter, Deepak L Bhatt, et al.
Pageof 2